Arakawa Satoshi, Ozawa Soji, Ando Takashi, Takeuchi Hiroya, Kitagawa Yuko, Kawase Jin, Oshima Hisanori, Nagata Hidetoshi, Atsuta Koji, Yoshida Rie, Kawabe Norihiko, Umemoto Shunji, Morise Zenichi, Horiguchi Akihiko
Department of Gastroenterological Surgery, Fujita Health University Bantane Hospital, Nagoya, Aichi, Japan.
Department of Gastroenterological Surgery, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Fujita Med J. 2019;5(1):14-20. doi: 10.20407/fmj.2017-025. Epub 2018 Dec 6.
The correlations of the ratio of long-/short-chain DNA fragments in blood with the existence of cancer and the clinicopathological features of colorectal cancer (CRC) were examined. The potential use of this ratio for diagnostic screening was evaluated.
DNA concentrations were amplified using Alu247 for long-chain DNA fragments and Alu115 for long- and short-chain DNA fragments. The Alu247/115 ratio was calculated for 60 patients with CRC and 24 healthy volunteers. The correlation of the Alu247/115 ratio with clinicopathological variables and the efficacy of this ratio as a tumor marker were examined. The Alu247/115 ratio cut-off value was set using a receiver operating characteristic (ROC) curve.
The Alu247/115 ratio was significantly higher in patients with CRC than in healthy volunteers (P<0.001). The Alu247/115 ratio was also significantly higher in patients with Dukes stage A or B CRC than in healthy volunteers (P=0.034) as well as in patients with Dukes C or D CRC than in those with Dukes A or B CRC (P=0.016). Among patients with CRC, the Alu247/115 ratio was significantly higher in those with than without venous invasion (P=0.031). Using the cut-off value set from the ROC curve, the sensitivity of the Alu247/115 ratio was significantly higher than that of the carcinoembryonic antigen level (P=0.004) or the carbohydrate antigen 19-9 level (P<0.001).
Our data suggest that the Alu247/115 ratio is a promising tool for highly sensitive and early detection of CRC.
研究血液中长链/短链DNA片段比例与癌症存在及结直肠癌（CRC）临床病理特征之间的相关性。评估该比例用于诊断筛查的潜在用途。
使用Alu247扩增长链DNA片段的DNA浓度，使用Alu115扩增长链和短链DNA片段的DNA浓度。计算60例CRC患者和24名健康志愿者的Alu247/115比例。研究Alu247/115比例与临床病理变量的相关性以及该比例作为肿瘤标志物的有效性。使用受试者工作特征（ROC）曲线设定Alu247/115比例的临界值。
CRC患者的Alu247/115比例显著高于健康志愿者（P<0.001）。Dukes A或B期CRC患者的Alu247/115比例也显著高于健康志愿者（P=0.034），Dukes C或D期CRC患者的该比例显著高于Dukes A或B期CRC患者（P=0.016）。在CRC患者中，有静脉侵犯者的Alu247/115比例显著高于无静脉侵犯者（P=0.031）。使用ROC曲线设定的临界值，Alu247/115比例的敏感性显著高于癌胚抗原水平（P=0.004）或糖类抗原19-9水平（P<0.001）。
我们的数据表明，Alu247/115比例是一种用于高灵敏度和早期检测CRC的有前景的工具。
